Protein May Aid Some Disease Treatments
Posted on: Tuesday, 7 March 2006, 18:00 CST
Purdue University scientists have discovered a molecular mechanism that may play a crucial role in cancer, Alzheimer's and heart disease treatments.
The researchers, using an imaging technique invented at Purdue, found a protein previously believed to be confined to the nucleus of healthy cells actually shuttles between the nucleus and cytoplasm -- the region of the cell surrounding the nucleus. Moreover, the protein's shuttling is controlled by another protein in the nucleus and its attachment to that second protein.
Our findings may provide a new avenue for the development of innovative treatments for certain cancers and other conditions, said Chang-Deng Hu, an assistant professor in Purdue's department of medicinal chemistry and molecular pharmacology.
The experiments were done using a line of teratocarcinoma malignant tumor cells from mice called F9, which, when subjected to the right biochemical signals, have the ability to alter their properties and are considered to be cancer stem cells.
If stem cells prove to be critical to cancer's resistance to treatment, new medications might be developed to target cancer stem cells while chemotherapy or radiation is administered, Hu said.
The research is detailed EMBO Journal, published by the European Molecular Biology Organization.
Source: United Press International
Related Articles
- Introgen's P53 Immunotherapy Drug Candidate to Advance Into Second Phase 2 Clinical Trial in Small Cell Lung Cancer With National Cancer Institute
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Geron, University of Edinburgh Form Collaboration for Development of Three Cell Types Derived From Human Embryonic Stem Cells
- Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum-Sensitive Non- Small Cell Lung Cancer
- Hana Biosciences Announces Positive Interim Results From a Phase I Trial of Talotrexin (PT-523) in Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
- Pivotal Phase III Tarceva Study Published in the New England Journal of Medicine Showed Survival Improvement in Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals Announces Tarceva Granted Approval in Canada for the Treatment of Advanced Non-Small Cell Lung Cancer
- The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-Small Cell Lung Cancer*: A Retrospective Analysis
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
- New Targets for Detection and Treatment of Small Cell Lung Cancer*
User Comments (0)
RSS Feeds